Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally.
$6.73-2.04%
报价 2026-11-13
市值
$304.5M
EV
$294.5M
PE (TTM)
9.7x
预期 PE (FY2026)
10.7x
52 周区间距高点 -32.2%
$2.77$9.93
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-13不在筛选范围:industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| AGENAgenus Inc. | $304.5M | -2.0% | +13.6% | 76.5% | 9.7x | 3.4x | – | |
| IRDOpus Genetics, Inc. | $331.1M | -2.0% | -4.4% | 99.9% | – | – | – | |
| TTRXTurn Therapeutics Inc. | $283.8M | -7.7% | – | 0% | – | – | – | |
| ZNTLZentalis Pharmaceuticals, Inc. | $167.1M | +1.2% | -22.2% | 0% | – | – | – | |
| FATEFate Therapeutics, Inc. | $149.2M | -4.5% | -10.6% | -343% | – | – | – | |
| INOInovio Pharmaceuticals, Inc. | $98.8M | -2.1% | +10800.0% | 0% | – | – | – | |
| HURATuHURA Biosciences, Inc. | $88.6M | -4.1% | +50.0% | 0% | – | – | – | |
| SEERSeer, Inc. | $87.6M | -1.3% | -4.1% | 47% | – | – | – | |
| PLRXPliant Therapeutics, Inc. | $43.2M | -5.8% | -24.2% | 0% | – | – | – | |
| 同行中位数 | – | – | -4.4% | 0% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。